Contact
News

AureoGen Announces Licensing Agreement with Merck

KALAMAZOO, Mich., Feb. 24, 2016 /PRNewswire/ — AureoGen Biosciences Inc. today announced a licensing agreement with Merck, known as MSD outside the United States and Canada, for the use of AureoGen’s proprietary chemistry and compounds for the development of medicines for infectious disease, including systemic fungal infections.

Read the rest of the article.

0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Time limit is exhausted. Please reload the CAPTCHA.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>